Latest Biotech News

Adlai Nortye licensed its pan‑RAS(ON) inhibitor AN‑9025 to Jiangsu Aosaikang Pharmaceutical (Ask Pharm) in an exclusive deal that gives Ask Pharm China commercialization rights. The oral small...

A federal judge in Maine issued a temporary restraining order halting the Health Resources and Services Administration’s 340B Rebate Model pilot that sought to de‑duplicate discounts for drugs...

Harbour Biomed and Yantai Lannacheng Biotechnology announced a long‑term strategic collaboration to develop next‑generation radionuclide‑drug conjugates for oncology. The partnership combines...

Boston‑area startup Nido Biosciences announced it will wind down after Phase II data fell below expectations, while Genmab terminated development of acasunlimab, a bispecific antibody that...

Biotech stocks rallied into 2026 as investors priced in renewed M&A activity and a friendlier interest-rate outlook. Exchange-traded fund XBI posted a sharp gain ahead of the JP Morgan Healthcare...

Insilico Medicine completed a long-anticipated Hong Kong listing and simultaneously disclosed new internal small-molecule programs. The company raised proceeds after multiple attempts to go...

Deal activity in 2025 centered on obesity therapeutics as GLP‑1 receptor agonists reshaped commercial priorities across biopharma. Companies pursuing complementary mechanisms or delivery formats...

Private financing into life‑science tools and diagnostics firms declined materially in H2 2025, with total investment down about 20% year over year, reflecting macro uncertainty and tighter...

The U.S. Food and Drug Administration approved Omeros Corp.’s narsoplimab (Yartemlea) for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA), marking the first...

China’s National Medical Products Administration granted approval to Innovent Biologics’ ipilimumab (Tabosun) in combination with sintilimab for neoadjuvant treatment of resectable...

Two late‑stage Phase III trials of setrusumab failed to meet primary endpoints, forcing Ultragenyx and Mereo into a reassessment of their brittle bone disease programs. The readouts triggered...

Multiple groups reported progress in in vivo gene‑editing and delivery in 2025, pushing the modality toward broader clinical translation. New strategies addressed tissue targeting, payload...

Verastem Oncology terminated an early‑stage trial of its MEK inhibitor Avmapki in lung cancer and said it will refocus resources on a KRAS‑targeting program. Separately, Genmab ended development...

Antibody‑drug conjugates diversified in 2025 as developers introduced new linkers, payloads and conjugation chemistries to expand target space and therapeutic windows. Industry reports catalog an...

Two late-stage Phase III readouts for setrusumab failed to meet primary endpoints, prompting immediate program and market fallout. Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc...

Genmab A/S announced it is terminating clinical development of acasunlimab, a bispecific antibody formerly partnered with BioNTech. The Danish developer said it will stop work on the asset after...

China’s National Medical Products Administration approved Innovent Biologics’ Tabosun (ipilimumab N01, IBI-310) in combination with sintilimab as a neoadjuvant treatment for resectable stage...

The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s four‑plex molecular assay on the new LIAISON Nes platform, enabling detection and differentiation of...

Nido Biosciences announced it will wind down operations in early 2026 after Phase II data fell short of expectations. The Boston‑area startup said the trial outcomes did not support further...

Adlai Nortye Ltd. granted Jiangsu Aosaikang Pharmaceutical Co. Ltd. (Ask Pharm) exclusive rights in China to AN‑9025, a pan‑RAS(ON) oral small molecule designed to target multiple RAS mutations...